Effects of platelet-activating factor antagonist CV-3988 in preservation of heart and lung for transplantation
- 31 October 1991
- journal article
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 52 (4), 1026-1032
- https://doi.org/10.1016/0003-4975(91)91272-w
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Free radicals and myocardial protection: A surgical viewpointThe Annals of Thoracic Surgery, 1989
- Metabolism and disposition of (RS)-2-methoxy-3-(octadecylcarbamoyloxy)propyl 2-(3-thiazolio)ethyl phosphate (MOTP) in rats and dogsXenobiotica, 1988
- The Clinical Assessment of Lung WaterChest, 1987
- REDUCTION OF SUSCEPTIBILITY TO LIPID PEROXIDATION BY DESFERRIOXAMINE IN RABBIT KIDNEYS SUBJECTED TO 24-HOUR COLD ISCHEMIA AND REPERFUSIONTransplantation, 1987
- Host-defense mechanisms responsible for lung injuryJournal of Allergy and Clinical Immunology, 1986
- A role for PAF-acether (platelet-activating factor) in platelet-dependent vascular diseases?Circulation, 1985
- Involvement of hydrogen peroxide and hydroxyl radical in the ‘oxygen paradox’: Reduction of creatine kinase release by catalase, allopurinol or deferoxamine, but not by superoxide dismutase**Journal of Molecular and Cellular Cardiology, 1985
- Inhibition by CV-3988 of the binding of [3H]-platelet activating factor (PAF) to the plateletBiochemical Pharmacology, 1985
- Desferrioxamine: a scavenger of superoxide radicals?Biochemical Pharmacology, 1984
- Inhibition of the iron-catalysed formation of hydroxyl radicals from superoxide and of lipid peroxidation by desferrioxamineBiochemical Journal, 1979